Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02323854 · ClinicalTrials.gov registry record · NA
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT02323854 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 15 participants.
The verdict
NCT02323854, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using a percutaneous approach in patients with primary, metastatic, or recurrent primary lung tumors.
Interventions
- PROCEDURE Surgical Resection
- DEVICE Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02323854
The ClinicalTrials.gov registry entry for NCT02323854 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgical Resection is the first listed.
NCT02323854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02323854 about?
NCT02323854 is a clinical study titled "The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)". Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using a percutaneous approach in patients with primary, metastatic, or recurrent primary lung tumors.
What is the current status of trial NCT02323854?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2015-01. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02323854?
The interventions under investigation include: Surgical Resection (PROCEDURE), Ablation (DEVICE).
Who is sponsoring clinical trial NCT02323854?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.